Ignyta 10-Q 11 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	RXDX
Entity Registrant Name	IGNYTA, INC.
Entity Central Index Key	1557421
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		25,262,023

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$43,043,953	$6,345,663
Short-term investment securities	44,908,611	63,200,563
Prepaid expenses and other current assets	1,531,545	1,731,521
Total current assets	89,484,109	71,277,747
Long-term investment securities	19,611,943	7,086,700
Fixed assets, net	6,551,061	6,280,909
Other assets	596,166	658,716
Total assets	116,243,279	85,304,072
Current liabilities:
Accounts payable	1,844,690	975,264
Accrued expenses and other liabilities	4,224,372	4,929,601
Note payable, current portion	3,500,000	1,400,000
Lease payable, current portion	173,847	171,638
Total current liabilities	9,742,909	7,476,503
Note payable, net of current portion and discount	16,797,225	18,830,136
Lease payable, net of current portion	299,889	344,188
Other long-term liabilities	2,581,747	2,705,319
Total liabilities	29,421,770	29,356,146
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.0001 par; 10,000,000 shares authorized; no shares issued or outstanding	0
Common stock, $0.0001 par; 150,000,000 shares authorized; 25,250,185 and 19,584,769 shares issued and outstanding, respectively	2,525	1,958
Additional paid-in capital	165,913,267	111,561,894
Accumulated deficit	-79,069,190	-55,562,586
Accumulated other comprehensive loss	-25,093	-53,340
Total stockholders' equity	86,821,509	55,947,926
Total liabilities and stockholders' equity	$116,243,279	$85,304,072

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	25,250,185	19,584,769
Common stock, shares outstanding	25,250,185	19,584,769

Condensed_Statements_of_Operat

Condensed Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Revenue	$0	$0
Expenses:
Research and development	20,215,446	2,182,580
General and administrative	3,024,256	1,761,548
Loss from operations	-23,239,702	-3,944,128
Other income (expense)
Interest income (expense)	-266,902	-135,642
Other income (expense)		-27,021
Total other expense, net	-266,902	-162,663
Net loss	-23,506,604	-4,106,791
Basic and diluted net loss per share	($1.15)	($0.28)
Weighted average shares outstanding - basic and diluted	20,465,612	14,501,276
Comprehensive loss:
Net loss	-23,506,604	-4,106,791
Unrealized gain (loss) on available for sale securities	28,247	-31,116
Comprehensive loss	($23,478,357)	($4,137,907)

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	($23,506,604)	($4,106,791)
Adjustments to reconcile net loss to net cash used in operating activities:
In-process research and development charge associated with asset acquisition	11,880,000
Stock-based compensation	1,032,216	436,279
Depreciation and amortization of fixed assets	372,080	48,600
Accretion and amortization on debt securities	352,760	83,185
Amortization of non-cash financing costs	67,089	74,360
Other		28,200
Increase (decrease) in cash resulting from changes in:
Prepaid expenses and other assets	262,526	-154,816
Accounts payable	869,426	303,464
Accrued expenses and other liabilities	-828,801	457,837
Net cash used in operating activities	-9,499,308	-2,829,682
Cash flows from investing activities:
Purchases of investment securities	-19,332,804	-49,368,366
Maturities and sales of investment securities	24,775,000	1,471,219
Purchases of fixed assets	-642,232	-62,646
Net cash provided by/(used in) investing activities	4,799,964	-47,959,793
Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs	41,438,524	51,581,843
Proceeds from exercise of stock options	1,200	2,905
Repurchase of common stock		-1,440
Payments on leases payable	-42,090
Net cash provided by financing activities	41,397,634	51,583,308
Net change in cash and cash equivalents	36,698,290	793,833
Cash and cash equivalents at beginning of period	6,345,663	51,803,716
Cash and cash equivalents at end of period	43,043,953	52,597,549
Supplemental disclosures of cash flow information:
Interest paid	449,400	115,333
Income taxes paid		5,304
Noncash investing and financing activities:
Unrealized gain (loss) on available for sale securities	$28,247	($31,116)

Organization_and_Basis_of_Pres

Organization and Basis of Presentation	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Organization and Basis of Presentation	1. ORGANIZATION AND BASIS OF PRESENTATION
	Organization and Nature of Operations
	Ignyta, Inc. (“Ignyta” or the “Company”) is incorporated in the state of Delaware and was founded in 2011 (with the name “NexDx, Inc.”). The Company changed its name to “Ignyta, Inc.” on October 8, 2012. The Company is a precision oncology biotechnology company dedicated to discovering or acquiring, then developing and commercializing, targeted new drugs for cancer patients whose tumors harbor specific molecular alterations, as well as novel chemotherapeutics that can potentially provide additional benefit to cancer patients. The Company is pursuing an integrated therapeutic and diagnostic, or Rx/Dx, strategy, where it anticipates pairing its product candidates with biomarker-based companion diagnostics that are designed to identify the patients who are most likely to benefit from the precisely targeted drugs the Company develops.
	On October 31, 2013, the Company merged with and into IGAS Acquisition Corp., a wholly owned subsidiary of Ignyta, Inc., a Nevada corporation previously named “Infinity Oil & Gas Company” (“Parent”), formerly a “shell company” under applicable rules of the Securities and Exchange Commission (the “SEC”). The Company changed its name to Ignyta Operating, Inc. in connection with this merger, and it survived the merger as a wholly owned subsidiary of Parent. In the merger, Parent acquired the business of the Company and continued the business operations of the Company. The merger is accounted for as a reverse merger and recapitalization, with the Company as the acquirer and Parent as the acquired company for financial reporting purposes. As a result, the assets and liabilities and the operations that are reflected in the historical financial statements prior to the merger are those of the Company and are recorded at the historical cost basis of the Company, and the consolidated financial statements after completion of the merger will include the assets and liabilities of Parent and the Company, the historical operations of the Company and the operations of the combined enterprise of Parent and the Company from and after the closing date of the merger. As a result of the accounting treatment of the merger and the change in Parent’s business and operations from a shell company to a precision oncology biotechnology company, a discussion of the past financial results of the shell company is not pertinent or material, and the following discussion and analysis of the Company’s financial condition and results of operations are based on the Company’s financial statements. On June 12, 2014, Parent merged with and into the Company, with the Company surviving the merger and changing its name to “Ignyta, Inc.” (the “Reincorporation Merger”). This Reincorporation Merger had no material impact on the accounting of the company.
	Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.
	Basis of Presentation
	The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information, the instructions to Form 10-Q and related SEC rules and regulations. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented. Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited financial statements should be read in conjunction with the Company’s audited financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014.
	Liquidity
	The Company had negative cash flow from operations of approximately $9.5 million during the first quarter of 2015 and, as of March 31, 2015, had an accumulated deficit of approximately $79.1 million. The Company is focused primarily on its development programs, and management believes such activities will result in the continued incurrence of significant research and development and other expenses related to those programs. The Company expects that it will need additional capital to further fund development of, and seek regulatory approvals for, its product candidates, and begin to commercialize any approved products. If the clinical trials for any of the Company’s products fail or produce unsuccessful results and those product candidates do not gain regulatory approval, or if any of its product candidates, if approved, fails to achieve market acceptance, the Company may never become profitable. Even if it achieves profitability in the future, the Company may not be able to sustain profitability in subsequent periods. The Company intends to cover its future operating expenses through cash on hand and through additional financing from existing and prospective investors. The Company cannot be sure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to the Company or to its stockholders.
	As of March 31, 2015, the Company had cash, cash equivalents and investment securities totaling $107.6 million. While the Company expects that its existing cash, cash equivalents and investment securities will enable it to fund its operations and capital expenditure requirements for at least the next twelve months, having insufficient funds may require the Company to delay, reduce, limit or terminate some or all of its development programs or future commercialization efforts or grant rights to develop and market product candidates that it would otherwise prefer to develop and market on its own. Failure to obtain adequate financing could eventually adversely affect the Company’s ability to operate as a going concern. If the Company raises additional funds from the issuance of equity securities, substantial dilution to its existing stockholders would likely result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict its ability to operate its business.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates. Significant estimates used in preparing the financial statements include those assumed in estimating expenses for the Company’s pre-clinical studies and clinical trials, computing the valuation allowance on deferred tax assets, and those assumed in calculating stock-based compensation expense.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments with an original maturity of 90 days or less when purchased to be cash equivalents. Cash equivalents primarily represent amounts invested in money market funds whose cost equals market value.
	Investment Securities
	Investment securities consist of corporate notes and bonds and commercial paper. The Company classifies its investment securities as available-for-sale at the time of purchase. All investment securities are recorded at estimated fair value. Unrealized gains and losses for available-for-sale investment securities are included in accumulated other comprehensive income, a component of stockholders’ equity. The Company evaluates its investment securities as of each balance sheet date to assess whether those with unrealized loss positions are other-than-temporarily impaired. Impairments are considered to be other-than-temporary if they are related to deterioration in credit risk or if it is likely that the Company will sell the securities before the recovery of its cost basis. Realized gains and losses and declines in value judged to be other-than-temporary are determined based on the specific identification method. No other-than-temporary impairment charges have been recognized since inception.
	Fair Value of Financial Instruments
	Financial assets and liabilities are measured at fair value, which is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.
	The Company’s financial instruments consist of cash and cash equivalents, investment securities, prepaid expenses and other assets, accounts payable, accrued expenses, and notes payable. The valuation of assets and liabilities is subject to fair value measurements using a three tiered approach, and fair value measurement is classified and disclosed in one of the following categories:
	Level 1:	Quoted prices in active markets for identical assets or liabilities;
	Level 2:	Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or
	Level 3:	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	Fair value estimates of these instruments at a specific point in time are made based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of judgment and therefore cannot be determined with precision.
	The book values of all cash and cash equivalents, prepaid expenses and other assets, accounts payable, accrued expenses and notes payable are reasonable estimates of their fair values because of the short nature of these items. The Company reports its available-for-sale securities at their estimated fair values based on quoted market prices for identical or similar instruments.
	Credit Risk
	Cash is invested in accordance with a policy approved by the Company’s board of directors which specifies the categories, allocations, and ratings of securities that the Company may consider for investment. Management does not believe that the Company’s cash, cash equivalents and available-for-sale investment securities have significant risk of default or illiquidity. This determination is based on discussions with the Company’s treasury managers and a review of the Company’s holdings. While the Company believes that its cash, cash equivalents and available-for-sale investment securities are well diversified and do not contain excessive risk, the Company cannot provide absolute assurance that its investments will not be subject to future adverse changes in market value.
	The Company maintains cash balances at various financial institutions. Accounts at these institutions are secured by the Federal Deposit Insurance Corporation. At times these balances exceed federally insured limits. The Company has not experienced any losses in such accounts. With respect to the Company’s available-for-sale investment securities, the primary exposure to market risk is interest rate sensitivity. This means that a change in prevailing interest rates may cause the value of the investment to fluctuate. For example, if the Company purchases a security that was issued with a fixed interest rate and the prevailing interest rate later rises, the value of this investment will probably decline. Currently, the Company’s holdings are in money market funds and available-for-sale investment securities, and therefore this interest rate risk is minimal. To minimize interest rate risk going forward, the Company intends to continue to maintain its portfolio of cash, cash equivalents and available-for-sale investment securities in a variety of securities consisting of money market funds and debt securities, all with various maturities. In general, money market funds are not subject to market risk because the interest paid on such funds fluctuates with the prevailing interest rate. The Company also attempts to time the maturities of its investments to correspond with expected cash needs, allowing it to avoid realizing any potential losses from having to sell securities prior to their maturities.
	Clinical Trial and Pre-Clinical Study Accruals
	The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances known to it at that time. Accrued expenses for pre-clinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by clinical research organizations, clinical trial investigational sites, and other clinical trial-related vendors. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing service fees, management estimates the time period over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other information available to it. If the Company underestimates or overestimates the activity or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in the Company’s accruals.
	Research and Development
	Costs incurred in connection with research and development activities are expensed as incurred. Research and development expenses consist of (i) external research and development expenses incurred under arrangements with third parties, such as contract research organizations, investigational sites and consultants; (ii) employee-related expenses, including salaries, benefits, travel and stock compensation expense; (iii) the cost of acquiring, developing and manufacturing clinical study materials; (iv) facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and laboratory and other supplies, and (v) license fees and other expenses relating to the acquisition of rights to our development programs.
	The Company enters into consulting, research and other agreements with commercial firms, researchers, universities and others for the provision of goods and services. Under such agreements, the Company may pay for services on a monthly, quarterly, project or other basis. Such arrangements are generally cancellable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided to the Company by its clinical sites and vendors and other information. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company.
	In certain circumstances, the Company is required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are deferred and are expensed when the activity has been performed or when the goods have been received.
	Stock-Based Compensation
	Stock-based compensation cost for equity awards to employees and members of the Company’s board of directors is measured at the grant date, based on the calculated fair value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over the requisite service period (generally the vesting period of the equity grant). Stock options issued to non-employees are accounted for at their estimated fair values determined using the Black-Scholes option-pricing model. The fair value of options granted to non-employees is re-measured as they vest, and the resulting increase in value, if any, is recognized as an expense during the period the related services are rendered. Restricted stock issued to non-employees is accounted for at its estimated fair value as it vests.
	Net Loss per Share
	Basic and diluted loss per common share have been computed by dividing the losses applicable to common stock by the weighted average number of common shares outstanding. The Company’s basic and fully diluted loss per common share calculations are the same since the increased number of shares that would be included in the diluted calculation from the assumed exercise of stock equivalents would be anti-dilutive to the net loss in each of the years shown in the financial statements.
	The calculations of net loss per share excluded potentially dilutive securities (consisting of outstanding options, warrants, restricted stock and restricted stock units) of approximately 4.1 million and 1.8 million shares as of March 31, 2015 and 2014, respectively.
	Recent Accounting Pronouncements
	In January 2015, the Financial Accounting Standards Board (“FASB”) issued an Accounting Standards Update (“ASU”) which eliminates the concept of extraordinary items. Extraordinary items are events and transactions that are distinguished by their unusual nature and by the infrequency of their occurrence. Eliminating the extraordinary classification simplifies income statement presentation by altogether removing the concept of extraordinary items from consideration. The standard is effective for the fiscal year beginning January 1, 2016. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. The Company does not believe the adoption of this standard will have a material impact on its financial position, results of operations or financial statement disclosures.
	In August 2014, the FASB issued an ASU which requires management to evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern, and to provide certain disclosures when it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued. Since this guidance is primarily around certain disclosures to the financial statements, the Company anticipates no impact on its financial position, results of operations or cash flows from adopting this standard. The Company intends to adopt this guidance at the beginning of its first quarter of fiscal year 2016.
	In May 2014, the FASB issued an ASU which supersedes or replaces nearly all revenue recognition guidance. The new guidance establishes a new control-based revenue recognition model, changes the basis for deciding when revenue is recognized over time or at a point in time and will expand disclosures about revenue. Companies may use either a full retrospective or a modified retrospective approach to adopt this guidance. The Company is evaluating which transition approach to use and its impact, if any, on its financial statements. This ASU is effective for the fiscal year beginning January 1, 2019. Early adoption is not permitted.
	Reclassifications.
	Certain reclassifications have been made to prior year amounts to conform to the current year presentation.

Asset_Acquisition

Asset Acquisition	3 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
Asset Acquisition	3. ASSET ACQUISITION
	On March 17, 2015, under the terms of an asset purchase agreement with Cephalon, Inc. (“Cephalon”), an indirect wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. (“Teva”), the Company acquired certain assets relating to four oncology development programs. The development programs that were purchased from Teva include:
		•	RXDX-105, a small molecule inhibitor of BRAF, EGFR and RET that is currently in a Phase I/II dose escalation clinical trial;
		•	RXDX-106, a small molecule, pseudo-irreversible inhibitor of AXL and cMET that is in late preclinical development;
		•	RXDX-107, a nanoformulation of a modified bendamustine with potential activity in solid tumors that is in late preclinical development; and
		•	RXDX-108, a small molecule inhibitor of the atypical kinase PKCiota that is in preclinical studies. The Company also acquired certain next generation PKCiota inhibitors in addition to the lead compound.
	Under the asset purchase agreement, the Company has acquired Cephalon’s right, title and interest in and to certain intellectual property, compounds, products, contracts, records, data and development supplies related to these programs (the “Purchased Assets”), and assumed certain related commitments. The Company did not acquire any marketable products, established customer or employee bases, or any established business, management, operational or resource management processes. Accordingly, the Company recorded this transaction as an asset purchase as opposed to a business combination. As consideration for the Purchased Assets, the Company issued to Cephalon 1,500,000 unregistered shares of the Company’s common stock and assumed certain other third-party obligations (see Note 8).
	The acquired assets are in various stages of drug development, ranging from preclinical stage to Phase I clinical trials. As such, the development plans are still being formulated and are as yet incomplete. The Company will be conducting further preclinical studies and making assessments of potential clinical development plans related to these compounds. As the success of the Company’s commercialization of these acquired compounds remains uncertain and the assets in question have no alternative future uses, the Company has recorded an in-process research and development charge of approximately $11.9 million during the three months ended March 31, 2015 based on the value of the net assets exchanged for the Teva assets.
	Under the provisions of the asset purchase agreement, the Company paid approximately $0.9 million to Cephalon for drug development supplies, which was included in research and development expenses for the three months ended March 31, 2015. Concurrent with the above transaction, Cephalon also entered into a subscription agreement with the Company whereby Cephalon agreed to purchase an additional 1,500,000 shares of the Company’s common stock at a price of $10.00 per share (see Note 9).
	In connection with the asset purchase agreement, the Company entered into a registration rights agreement with Cephalon pursuant to which the Company has agreed to register the shares of the Company’s common stock held by Cephalon. Under the terms of the registration rights agreement, the Company is required to use best efforts to file a registration statement with the SEC on or before December 17, 2015 and to cause such registration statement to be declared effective by the SEC within 90 days after the date the registration statement is filed. The Company may be liable for liquidated damages if it fails to meet such timelines or if the registration statement ceases to remain effective after being declared effective, subject to certain exceptions. The amount of the liquidated damages per applicable thirty-day period is one percent of the aggregate purchase price of the registrable securities then held by each holder, subject to an aggregate cap of ten percent. The Company also agreed to other customary obligations regarding registration, including matters relating to indemnification, maintenance of the registration statement and payment of certain expenses.

Investment_Securities

Investment Securities	3 Months Ended
	Mar. 31, 2015
Investments Schedule [Abstract]
Investment Securities	4. INVESTMENT SECURITIES
	Investments
	The following tables summarize the Company’s investment securities as of March 31, 2015 and December 31, 2014:
		March 31, 2015 (in thousands)
		Cost		Gross		Gross			Fair
				Unrealized		Unrealized			Market
				Gains		Losses			Value
	Available-for-sale securities:
	Commercial paper, short-term	$	2,498	$	—	$	—		$	2,498
	Corporate debt securities, short-term		42,421		5		(15	)		42,411
	Corporate debt securities, long-term		19,627		8		(23	)		19,612
	Total	$	64,546	$	13	$	(38	)	$	64,521
		December 31, 2014 (in thousands)
		Cost		Gross		Gross			Fair
				Unrealized		Unrealized			Market
				Gains		Losses			Value
	Available-for-sale securities:
	Commercial paper, short-term	$	3,896	$	—	$	—		$	3,896
	Corporate debt securities, short-term		59,343		—		(38	)		59,305
	Corporate debt securities, long-term		7,102		—		(15	)		7,087
	Total	$	70,341	$	—	$	(53	)	$	70,288
	All of the Company’s available-for-sale investment securities held at March 31, 2015 had maturity dates of less than 18 months. The Company determines the appropriate designation of investments at the time of purchase and reevaluates such designation as of each balance sheet date. Investment securities classified as short-term investments have maturity dates of less than one year from the balance sheet date, while securities classified as long-term investments have maturity dates of greater than one year from the balance sheet date. The cost of securities sold is based on the specific identification method. Amortization of premiums, accretion of discounts, interest, dividend income, and realized gains and losses are included in investment income.
	None of the Company’s available-for-sale investment securities was in a material unrealized loss position at March 31, 2015. The Company reviewed its investment holdings as of March 31, 2015 and determined that its unrealized losses were not considered to be other-than-temporary based upon (i) the financial strength of the issuing institution and (ii) the fact that all securities have been in an unrealized loss position for less than twelve months. As such, the Company has not recognized any impairment in its financial statements related to its available-for-sale securities.
	The Company has not realized any significant gains or losses on sales of available-for-sale investment securities during 2015 or 2014.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	5. FAIR VALUE MEASUREMENTS
	The fair value of the Company’s cash, cash equivalents and available-for-sale investment securities at March 31, 2015 and December 31, 2014 were as follows (in thousands):
		March 31, 2015								December 31, 2014
		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Cash and cash equivalents	$	43,043	$	—	$	—	$	43,043	$	6,346	$	—	$	—	$	6,346
	Short-term investments:
	Commercial paper		—		2,498		—		2,498		—		3,896		—		3,896
	Corporate debt securities		—		42,411		—		42,411		—		59,305		—		59,305
	Total short-term investments		—		44,909		—		44,909		—		63,201		—		63,201
	Long-term investments:
	Corporate debt securities		—		19,612		—		19,612		—		7,087		—		7,087
	Total long-term investments		—		19,612		—		19,612		—		7,087		—		7,087
	Total assets measured at fair value	$	43,043	$	64,521	$	—	$	107,565	$	6,346	$	70,288	$	—	$	76,634
	The Company holds available-for-sale securities that consist of highly liquid, investment grade debt securities. The Company determines the fair value of its available-for-sale securities based upon one or more valuations reported by its investment accounting and reporting service provider. The investment service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service. Such valuations may be based on trade prices in active markets for identical assets or liabilities (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curves, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, and broker and dealer quotes, as well as other relevant economic measures.

Fixed_Assets

Fixed Assets	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Fixed Assets	6. FIXED ASSETS
	Carrying Value of Fixed Assets
	Fixed assets consisted of the following at March 31, 2015 and December 31, 2014:
		March 31,			December 31,
		2015			2014
	Manufacturing and lab equipment	$	4,414,172		$	3,837,967
	Office furniture		288,030			278,895
	Computer equipment and software		523,522			471,415
	Leasehold improvements		2,331,748			2,326,963
			7,557,472			6,915,240
	Less accumulated depreciation and amortization		(1,006,411	)		(634,331	)
		$	6,551,061		$	6,280,909
	Depreciation expense for the three months ended March 31, 2015 and 2014 was $372,080 and $48,600, respectively.
	Capital Leases
	The Company has entered into capital lease agreements for the purchase of certain lab equipment. Property held under capital leases was as follows:
		March 31,			December 31,
		2015			2014
	Manufacturing and lab equipment	$	635,730		$	635,730
	Less accumulated depreciation and amortization		(65,218	)		(16,716	)
		$	570,512		$	619,014
	Depreciation expense related to the capital lease equipment was $48,502 and $0 for the three months ended March 31, 2015 and 2014, respectively. As of March 31, 2015, future remaining minimum payments under capital leases totaled approximately $507,000.

Notes_Payable

Notes Payable	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Notes Payable	7. NOTES PAYABLE
	On September 30, 2014, the Company entered into an amended and restated loan and security agreement (the “New Loan Agreement”) with Silicon Valley Bank (“SVB”). The New Loan Agreement replaced the prior loan and security agreement (the “Loan Agreement”) which was first entered into in June 2012, amended in February 2013 and amended and restated in December 2013. The amount borrowed under the New Loan Agreement was increased from $10,000,000 to $21,000,000, with an option to receive an additional $10,000,000, which may be drawn down at any time prior to September 30, 2015 provided the Company has initiated the Phase IIa portion of its ongoing, global Phase I/II clinical study of entrectinib and subject to other customary conditions for funding. All principal and interest due on the prior Loan Agreement was paid in full and the Company was advanced the net proceeds on September 30, 2014. Payments of principal and interest are due on the New Loan Agreement on a fully amortized basis of 30 months in equal monthly installments, commencing after a twelve-month period of interest only payments, such that all amounts owed under the New Loan Agreement will mature on April 1, 2018. The number of months of interest-only payments and the number of months over which the principal will be amortized each will be increased by six months if the second loan tranche has been drawn down or the Company has raised net proceeds of at least $50 million through the offering of its equity securities, in each case prior to October 31, 2015. Upon the final maturity date, the Company will also owe to the lender a final payment equal to 3% of the full principal amount under the New Loan Agreement. The final payment of $630,000, which is based on the initial amount borrowed under the New Loan Agreement, is presented as a debt discount on the related debt to be amortized to interest expense. Interest on the note was fixed on the date of funding at 8.56%. Pursuant to the New Loan Agreement, the Company is bound by certain affirmative and negative covenants setting forth actions that it must and must not take during the term thereof. Upon the occurrence of an event of default under the New Loan Agreement, subject to cure periods for certain events of default, all amounts owed by the Company thereunder shall begin to bear interest at a rate of 11.56% and may be declared immediately due and payable by SVB. The Company has granted SVB a security interest in substantially all of its personal property, rights and assets, other than intellectual property, to secure the payment of all amounts owed to SVB under the New Loan Agreement. The Company has also agreed not to encumber any of its intellectual property without SVB’s prior written consent.
	In connection with entering into the New Loan Agreement, the Company issued to SVB and its affiliate warrants to purchase an aggregate of 37,849 shares of its common stock. The fair value of the warrants has been recorded as a debt discount on the related debt and is being amortized to interest expense over the term of the New Loan Agreement.
	Future minimum principal payments under the Company’s notes payable are as follows:
	Year ending December 31,
	2015 (9 months)	$	1,400,000
	2016		8,400,000
	2017		8,400,000
	2018		2,800,000
	Total	$	21,000,000
	If the Company draws down the second loan tranche, it will issue to SVB and its affiliate additional warrants which will be exercisable immediately and have a term of seven years. Those warrants will be exercisable for an aggregate number of shares equal to $135,500 divided by the lower of (a) the trailing 10-day average of the closing price of the Company’s common stock on the Nasdaq Capital Market prior to the funding date of the second loan tranche and (b) the closing price of the Company’s common stock on the Nasdaq Capital Market on the funding date of the second loan tranche, at an exercise price equal to such divisor.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. COMMITMENTS AND CONTINGENCIES
	License agreements
	Entrectinib. The Company entered into a license agreement with Nerviano Medical Sciences S.r.l. (“NMS”) on October 10, 2013, which was amended on October 25, 2013, became effective on November 6, 2013, and was amended December 12, 2014. The agreement grants the Company exclusive global rights to develop and commercialize entrectinib, as well as a second product candidate, RXDX-102. As a result of the Phase I results relating to entrectinib that have been seen to date, the Company designated RXDX-102 as a back-up compound to entrectinib. Accordingly, the Company will not devote further development resources to RXDX-102. The Company’s development rights under the license agreement are exclusive for the term of the agreement with respect to entrectinib and RXDX-102 and also, as to NMS, are exclusive for a five-year period with respect to any product candidate with activity against the target proteins of entrectinib and RXDX-102, and include the right to grant sublicenses. The Company is obligated under the license agreement to use commercially reasonable efforts to develop and commercialize a product based on either or both of entrectinib and RXDX-102, at its expense.
	The terms of the license agreement provided for an up-front payment to NMS of $7.0 million, which was paid in November 2013 and expensed as research and development (as no future benefit was determined to exist at that time). When and if commercial sales of a product based on either or both of entrectinib or RXDX-102 begin, the Company will be obligated to pay NMS tiered royalties ranging from a mid-single digit percentage to a low double digit percentage (between 10% and 15%) of net sales, depending on the amount of net sales, with standard provisions for royalty offsets to the extent it obtains any rights from third parties to commercialize the product. The Company was also obligated under the terms of the license agreement to engage NMS to perform services valued at $1.0 million prior to December 31, 2014, which obligation had been met prior to that time. The license agreement also requires that the Company makes development and regulatory milestone payments to NMS of up to $105.0 million in the aggregate if specified clinical study initiations and regulatory approvals are achieved across multiple products or indications. Pursuant to the December 2014 amendment to the agreement, the Company paid the initial milestone payment of $10.0 million to NMS in December 2014, which was expensed as research and development (as no future benefit was determined to exist at that time).
	RXDX-103 and RXDX-104. On August 4, 2014, the Company entered into a second license agreement with NMS. The agreement grants the Company exclusive global rights to develop and commercialize RXDX-103, as well as a second development program, RXDX-104. Based on preclinical activities relating to RXDX-104, in December 2014, the Company decided to discontinue development of RXDX-104, and the Company will not devote further development resources to this program. The Company’s rights under the agreement are exclusive for the term of the agreement with respect to RXDX-103 and RXDX-104 and also, as to NMS, are exclusive for a five-year period with respect to any product candidate with activity against the target proteins of RXDX-103 and RXDX-104, subject to NMS’s right to develop and commercialize a predecessor compound to RXDX-103 solely for animal indications. The Company is obligated under the license agreement to use commercially reasonable efforts to develop and commercialize a product based on either or both of RXDX-103 and RXDX-104, at its expense.
	Under the license agreement, the Company made an up-front payment to NMS of $3.5 million in August 2014, which was expensed to research and development (as no future benefit was determined to exist at that time). When and if commercial sales of a product based on either of RXDX-103 or RXDX-104 begin, the Company will be obligated to pay NMS tiered royalties ranging from a mid-single digit percentage to a low double digit percentage of net sales, depending on annual amounts of net sales, with standard provisions for royalty offsets to the extent it is required to obtain any rights from third parties to commercialize either RXDX-103 or RXDX-104. The Company is also required to make development and regulatory milestone payments to NMS of up to $68.0 million in the aggregate for RXDX-103 if specified clinical study initiations and regulatory approvals are achieved across multiple products or indications.
	RXDX-105 and RXDX-106. In connection with the March 2015 asset acquisition from Cephalon, we assumed all rights and obligations under the collaboration agreement dated November 3, 2006, as amended April 17, 2009, between Cephalon, Inc. and Daiichi Sankyo Company, Limited (“Daiichi Sankyo”), as successor-in-interest to Ambit Biosciences Corporation. The collaboration was for the purpose of identifying and developing clinical candidates that demonstrate activity towards the two designated target kinases of the collaboration: the BRAF kinase and the AXL kinase. Under the agreement, both parties contributed certain intellectual property to the collaboration and agreed to a period of exclusivity during which neither party would engage in any research related to a collaboration target compound with any third-party. The collaboration portion of the agreement ended in November 2009, but the agreement remains in effect on a product-by-product, country-by-country basis until all royalty obligations expire. Both parties have a right to terminate the agreement if the other party enters bankruptcy or upon an uncured breach by the other party. The Company may also terminate the agreement in its discretion upon 90 days’ written notice to Daiichi Sankyo.
	The Company is solely responsible for worldwide clinical development and commercialization of collaboration compounds, subject to the option of Daiichi Sankyo, exercisable during certain periods following completion of the first proof-of-concept study in humans and only with the consent of the Company, to co-develop and co-promote RXDX-105. If the Company decides to discontinue development of the RXDX-105 program, it must give written notice to Daiichi Sankyo, which will have the right to assume control of that program, subject to diligence obligations and payment of the milestones and royalties to the Company that would otherwise have been paid to Daiichi Sankyo had the Company maintained responsibility for the program.
	The agreement requires the Company to make development, regulatory and sales milestone payments to Daiichi Sankyo of up to $44.5 million in the aggregate for RXDX-105, and up to $47.5 million in payments upon the achievement of development, regulatory and sales milestones for RXDX-106. When and if commercial sales of a product based on either of RXDX-105 or RXDX-106 begin, the Company will be obligated to pay Daiichi Sankyo tiered royalties ranging from a mid-single digit percentage to a low double digit percentage of net sales, depending on annual amounts of net sales, with standard provisions for royalty offsets to the extent it is required to obtain any rights from third parties to commercialize either RXDX-105 or RXDX-106. Royalties are payable to Daiichi Sankyo on a product-by-product, country-by-country basis beginning on the date of the first commercial sale in a country and ending on the later of 10 years after the date of such sale in that country or the expiration date of the last to expire licensed patent covering the product in that country.
	RXDX-108. In connection with the March 2015 asset acquisition from Cephalon, the Company assumed all rights and obligations under the license agreement dated January 20, 2014, between Teva Branded Pharmaceutical Products R&D, Inc. and Cancer Research Technology Limited (“CRT”). The agreement grants the Company exclusive global rights to develop and commercialize RXDX-108. The Company also received rights to certain other next generation PKCiota inhibitors. The Company is obligated under the license agreement to use commercially reasonable efforts to develop and commercialize a product based on RXDX-108 or the licensed intellectual property, at its expense.
	The agreement remains in effect on a product-by-product, country-by-country basis until all royalty obligations expire. Both parties have a right to terminate the agreement if the other party enters bankruptcy or upon an uncured breach by the other party. CRT may also terminate the agreement upon a change in control of the Company by a third party that develops, sells or manufactures tobacco products.
	The license agreement requires the Company to make development, regulatory and sales milestone payments to CRT of up to $57.0 million in the aggregate. When and if commercial sales of a product based on the licensed intellectual property begin, the Company will be obligated to pay CRT tiered royalties ranging from a mid-single digit percentage to a low double digit percentage of net sales, depending on annual amounts of net sales. Royalties are payable to CRT on a product-by-product, country-by-country basis beginning on the date of the first commercial sale in a country and ending on the later of 10 years after the date of such sale in that country or the expiration date of the last to expire licensed patent covering the product in that country.
	Commitments
	On March 31, 2014, the Company entered into an agreement with a contract research organization for clinical studies to be conducted both within and outside the U.S., at an estimated cost of approximately $10.0 million over a two-year period. Through March 31, 2015, approximately $2.7 million has been incurred under this agreement.
	The Company leases office space and lab equipment under non-cancelable operating leases expiring on various dates through October 2019. Rent expense under those operating leases for the three months ended March 31, 2015 and 2014 was $133,137 and $69,602, respectively. Future minimum lease payments under the Company’s operating leases totaled $3.5 million as of March 31, 2015.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Stockholders' Equity	9. STOCKHOLDERS’ EQUITY
	Authorized Shares
	The Company is authorized to issue 150,000,000 shares of common stock and 10,000,000 shares of preferred stock, with the preferred stock having the rights, preferences and privileges that the Board of Directors may determine from time to time. Each share of the Company’s common stock is entitled to one vote, and all shares rank equally as to voting and other matters.
	Restricted Stock
	The Company issued restricted shares in 2011 and 2013. The Company’s restricted stock arrangements allow it to repurchase any unvested shares of stock in the event the holder ceases providing services to the Company. In February 2014, the Company repurchased 400,000 of such restricted shares. No shares were repurchased by the Company during the first quarter of 2015.
	At March 31, 2015, the Company had 37,506 shares of restricted stock outstanding that were subject to future vesting (through 2016).
	Stock Offerings
	In March 2015, concurrent with its asset acquisition agreement with Cephalon (see Note 3), the Company issued and sold 4,158,750 shares of common stock at $10.00 per share to Cephalon and several additional investors in a secondary public offering. The net proceeds from this offering totaled $41.4 million (after deducting transaction costs of $149,000).
	In March 2014, the Company completed a secondary public stock offering providing for the issuance and sale to investors of an aggregate of 6,031,750 shares of its common stock at a purchase price of $9.15 per share for net proceeds of approximately $55.2 million (after deducting transaction costs of $3.6 million).
	Warrants
	As of March 31, 2015, the Company has outstanding common stock warrants to purchase up to an aggregate of 79,516 shares of its common stock. The warrants have exercise prices ranging from $3.00 per share to $7.52 per share, and expire at various dates through September 30, 2021. In April 2015, common stock warrants to purchase 16,666 shares were converted by the holder on a net-exercise basis into 11,838 shares of common stock.

Equity_Awards

Equity Awards	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Equity Awards	10. EQUITY AWARDS
	Equity Incentive Plans
	The Company adopted the 2014 Incentive Award Plan (the “2014 Plan”) on June 11, 2014. The 2014 Plan provides for the issuance of equity awards to employees and non-employees of 3,000,000 shares, plus one share for each share subject to a stock option that was outstanding under the Company’s 2011 Stock Incentive Plan, as amended (the “2011 Plan”) prior to the effective date of the 2014 Plan that expires, is forfeited or is settled in cash. As of March 31, 2015, 1,250,396 shares remain available under the 2014 Plan. Prior to the adoption of the 2014 Plan, the Company granted equity awards under the 2011 Plan and the 2014 Employment Inducement Incentive Award Plan (the “Inducement Plan”). No additional equity grants may be made by the Company under either the 2011 Plan or the Inducement Plan.
	Options granted under the Company’s equity plans are exercisable at various dates and will expire no more than ten years from their dates of grant. The exercise price of each option to be granted under the 2014 Plan shall be determined by the administrator of the 2014 Plan, which is the Company’s Board of Directors or the Compensation Committee thereof, and shall not be less than 100% of the fair market value of the Company’s common stock on the date the option is granted. Generally, options are granted with an exercise price equal to the fair market value of the Company’s common stock on the date of the option grant. For holders of more than 10% of the Company’s total combined voting power of all classes of stock, incentive stock options may not be granted at less than 110% of the fair market value of the Company’s common stock on the date of grant and for a term not to exceed five years.
	Stock-Based Compensation
	The following table summarizes stock-based compensation expense for all equity awards to employees and non-employees:
			Three months ended			Three months ended
			March 31, 2015			March 31, 2014
	Included in research and development		$	468,614		$	174,637
	Included in general and administrative			563,602			261,642
	Total stock-based compensation expense		$	1,032,216		$	436,279
	As of March 31, 2015, unrecognized stock-based compensation expense related to unvested stock-based awards granted under the Company’s equity incentive plans totaled $12.5 million, which is expected to be recognized over a weighted-average period of 3.31 years.
	Fair Value of Equity Awards
	The Company utilizes the Black-Scholes option pricing model to value awards under its equity plans. Key valuation assumptions include:
		•		Volatility – volatility is the measure of the amount by which a financial variable, such as a share price, has or is expected to fluctuate during a period. The Company considered the historical volatility of peer companies and business/ economic considerations in order to estimate expected volatility (as the Company not been publicly traded for a significant period).
		•		Risk-Free Interest Rate – this is the U.S. Treasury rate for the day of each option grant during the quarter having a term that most closely resembles the expected life of the option.
		•		Dividend Yield – the Company has never declared or paid dividends on common stock and has no plans to do so.
		•		Expected Life of the Option Term – this is the period of time that the options granted are expected to remain unexercised. Options granted during the period have a maximum contractual term of ten years. The Company estimates the expected life of the option term for employee option grants based on the simplified method (as defined in Staff Accounting Bulletin 110). For non-employee option grants, this is the remaining contractual term of the option.
	Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company assesses the forfeiture rate on an annual basis and revises the rate when deemed necessary.
	During the first quarter of 2015, the fair value of options granted was estimated using the following weighted-average assumptions:
			Fiscal 2015
	Volatility			69.67	%
	Risk free interest rate			1.56	%
	Dividend yield			0	%
	Weighted-average expected life of option			6.2 years
	The estimated weighted-average per-share fair value of stock options granted during the first quarter of 2015 was $4.68.
	Stock Option Activity
	A summary of the Company’s stock option activity and related information is as follows:
			Options			Weighted-		Weighted-		Aggregate
			Outstanding			Average		Average		Intrinsic
						Exercise		Remaining		Value
						Price		Term
	Balance at December 31, 2014			2,991,656		$	6.67		9.21	$	2,482,181
	Granted			998,991			7.47
	Exercised			(6,666	)		0.18
	Forfeited			(21,068	)		7.78
	Balance at March 31, 2015			3,962,913		$	6.87		9.19	$	12,191,424
	Exercisable at March 31, 2015			593,134		$	5.16		8.54	$	2,842,885
	Restricted Stock Units
	In 2015, the Company issued 90,000 restricted stock units (“RSUs”) to employees under the 2014 Plan with vesting to occur on either the fourth or fifth anniversary of the grant date. All of these RSUs were outstanding and subject to future vesting as of March 31, 2015.

Organization_and_Basis_of_Pres1

Organization and Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Organization and Nature of Operations	Organization and Nature of Operations
	Ignyta, Inc. (“Ignyta” or the “Company”) is incorporated in the state of Delaware and was founded in 2011 (with the name “NexDx, Inc.”). The Company changed its name to “Ignyta, Inc.” on October 8, 2012. The Company is a precision oncology biotechnology company dedicated to discovering or acquiring, then developing and commercializing, targeted new drugs for cancer patients whose tumors harbor specific molecular alterations, as well as novel chemotherapeutics that can potentially provide additional benefit to cancer patients. The Company is pursuing an integrated therapeutic and diagnostic, or Rx/Dx, strategy, where it anticipates pairing its product candidates with biomarker-based companion diagnostics that are designed to identify the patients who are most likely to benefit from the precisely targeted drugs the Company develops.
	On October 31, 2013, the Company merged with and into IGAS Acquisition Corp., a wholly owned subsidiary of Ignyta, Inc., a Nevada corporation previously named “Infinity Oil & Gas Company” (“Parent”), formerly a “shell company” under applicable rules of the Securities and Exchange Commission (the “SEC”). The Company changed its name to Ignyta Operating, Inc. in connection with this merger, and it survived the merger as a wholly owned subsidiary of Parent. In the merger, Parent acquired the business of the Company and continued the business operations of the Company. The merger is accounted for as a reverse merger and recapitalization, with the Company as the acquirer and Parent as the acquired company for financial reporting purposes. As a result, the assets and liabilities and the operations that are reflected in the historical financial statements prior to the merger are those of the Company and are recorded at the historical cost basis of the Company, and the consolidated financial statements after completion of the merger will include the assets and liabilities of Parent and the Company, the historical operations of the Company and the operations of the combined enterprise of Parent and the Company from and after the closing date of the merger. As a result of the accounting treatment of the merger and the change in Parent’s business and operations from a shell company to a precision oncology biotechnology company, a discussion of the past financial results of the shell company is not pertinent or material, and the following discussion and analysis of the Company’s financial condition and results of operations are based on the Company’s financial statements. On June 12, 2014, Parent merged with and into the Company, with the Company surviving the merger and changing its name to “Ignyta, Inc.” (the “Reincorporation Merger”). This Reincorporation Merger had no material impact on the accounting of the company.
	Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.
Basis of Presentation	Basis of Presentation
	The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information, the instructions to Form 10-Q and related SEC rules and regulations. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented. Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited financial statements should be read in conjunction with the Company’s audited financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014.
Liquidity	Liquidity
	The Company had negative cash flow from operations of approximately $9.5 million during the first quarter of 2015 and, as of March 31, 2015, had an accumulated deficit of approximately $79.1 million. The Company is focused primarily on its development programs, and management believes such activities will result in the continued incurrence of significant research and development and other expenses related to those programs. The Company expects that it will need additional capital to further fund development of, and seek regulatory approvals for, its product candidates, and begin to commercialize any approved products. If the clinical trials for any of the Company’s products fail or produce unsuccessful results and those product candidates do not gain regulatory approval, or if any of its product candidates, if approved, fails to achieve market acceptance, the Company may never become profitable. Even if it achieves profitability in the future, the Company may not be able to sustain profitability in subsequent periods. The Company intends to cover its future operating expenses through cash on hand and through additional financing from existing and prospective investors. The Company cannot be sure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to the Company or to its stockholders.
	As of March 31, 2015, the Company had cash, cash equivalents and investment securities totaling $107.6 million. While the Company expects that its existing cash, cash equivalents and investment securities will enable it to fund its operations and capital expenditure requirements for at least the next twelve months, having insufficient funds may require the Company to delay, reduce, limit or terminate some or all of its development programs or future commercialization efforts or grant rights to develop and market product candidates that it would otherwise prefer to develop and market on its own. Failure to obtain adequate financing could eventually adversely affect the Company’s ability to operate as a going concern. If the Company raises additional funds from the issuance of equity securities, substantial dilution to its existing stockholders would likely result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict its ability to operate its business.
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. Actual results could differ from those estimates. Significant estimates used in preparing the financial statements include those assumed in estimating expenses for the Company’s pre-clinical studies and clinical trials, computing the valuation allowance on deferred tax assets, and those assumed in calculating stock-based compensation expense.
Cash and Cash Equivalents	Cash and Cash Equivalents
	The Company considers all highly liquid investments with an original maturity of 90 days or less when purchased to be cash equivalents. Cash equivalents primarily represent amounts invested in money market funds whose cost equals market value.
Investment Securities	Investment Securities
	Investment securities consist of corporate notes and bonds and commercial paper. The Company classifies its investment securities as available-for-sale at the time of purchase. All investment securities are recorded at estimated fair value. Unrealized gains and losses for available-for-sale investment securities are included in accumulated other comprehensive income, a component of stockholders’ equity. The Company evaluates its investment securities as of each balance sheet date to assess whether those with unrealized loss positions are other-than-temporarily impaired. Impairments are considered to be other-than-temporary if they are related to deterioration in credit risk or if it is likely that the Company will sell the securities before the recovery of its cost basis. Realized gains and losses and declines in value judged to be other-than-temporary are determined based on the specific identification method. No other-than-temporary impairment charges have been recognized since inception.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	Financial assets and liabilities are measured at fair value, which is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.
	The Company’s financial instruments consist of cash and cash equivalents, investment securities, prepaid expenses and other assets, accounts payable, accrued expenses, and notes payable. The valuation of assets and liabilities is subject to fair value measurements using a three tiered approach, and fair value measurement is classified and disclosed in one of the following categories:
	Level 1:	Quoted prices in active markets for identical assets or liabilities;
	Level 2:	Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or
	Level 3:	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	Fair value estimates of these instruments at a specific point in time are made based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of judgment and therefore cannot be determined with precision.
	The book values of all cash and cash equivalents, prepaid expenses and other assets, accounts payable, accrued expenses and notes payable are reasonable estimates of their fair values because of the short nature of these items. The Company reports its available-for-sale securities at their estimated fair values based on quoted market prices for identical or similar instruments.
Credit Risk	Credit Risk
	Cash is invested in accordance with a policy approved by the Company’s board of directors which specifies the categories, allocations, and ratings of securities that the Company may consider for investment. Management does not believe that the Company’s cash, cash equivalents and available-for-sale investment securities have significant risk of default or illiquidity. This determination is based on discussions with the Company’s treasury managers and a review of the Company’s holdings. While the Company believes that its cash, cash equivalents and available-for-sale investment securities are well diversified and do not contain excessive risk, the Company cannot provide absolute assurance that its investments will not be subject to future adverse changes in market value.
	The Company maintains cash balances at various financial institutions. Accounts at these institutions are secured by the Federal Deposit Insurance Corporation. At times these balances exceed federally insured limits. The Company has not experienced any losses in such accounts. With respect to the Company’s available-for-sale investment securities, the primary exposure to market risk is interest rate sensitivity. This means that a change in prevailing interest rates may cause the value of the investment to fluctuate. For example, if the Company purchases a security that was issued with a fixed interest rate and the prevailing interest rate later rises, the value of this investment will probably decline. Currently, the Company’s holdings are in money market funds and available-for-sale investment securities, and therefore this interest rate risk is minimal. To minimize interest rate risk going forward, the Company intends to continue to maintain its portfolio of cash, cash equivalents and available-for-sale investment securities in a variety of securities consisting of money market funds and debt securities, all with various maturities. In general, money market funds are not subject to market risk because the interest paid on such funds fluctuates with the prevailing interest rate. The Company also attempts to time the maturities of its investments to correspond with expected cash needs, allowing it to avoid realizing any potential losses from having to sell securities prior to their maturities.
Clinical Trial and Pre-Clinical Study Accruals	Clinical Trial and Pre-Clinical Study Accruals
	The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances known to it at that time. Accrued expenses for pre-clinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by clinical research organizations, clinical trial investigational sites, and other clinical trial-related vendors. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing service fees, management estimates the time period over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other information available to it. If the Company underestimates or overestimates the activity or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in the Company’s accruals.
Research and Development	Research and Development
	Costs incurred in connection with research and development activities are expensed as incurred. Research and development expenses consist of (i) external research and development expenses incurred under arrangements with third parties, such as contract research organizations, investigational sites and consultants; (ii) employee-related expenses, including salaries, benefits, travel and stock compensation expense; (iii) the cost of acquiring, developing and manufacturing clinical study materials; (iv) facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and laboratory and other supplies, and (v) license fees and other expenses relating to the acquisition of rights to our development programs.
	The Company enters into consulting, research and other agreements with commercial firms, researchers, universities and others for the provision of goods and services. Under such agreements, the Company may pay for services on a monthly, quarterly, project or other basis. Such arrangements are generally cancellable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided to the Company by its clinical sites and vendors and other information. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company.
	In certain circumstances, the Company is required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are deferred and are expensed when the activity has been performed or when the goods have been received.
Stock-Based Compensation	Stock-Based Compensation
	Stock-based compensation cost for equity awards to employees and members of the Company’s board of directors is measured at the grant date, based on the calculated fair value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over the requisite service period (generally the vesting period of the equity grant). Stock options issued to non-employees are accounted for at their estimated fair values determined using the Black-Scholes option-pricing model. The fair value of options granted to non-employees is re-measured as they vest, and the resulting increase in value, if any, is recognized as an expense during the period the related services are rendered. Restricted stock issued to non-employees is accounted for at its estimated fair value as it vests.
Net Loss per Share	Net Loss per Share
	Basic and diluted loss per common share have been computed by dividing the losses applicable to common stock by the weighted average number of common shares outstanding. The Company’s basic and fully diluted loss per common share calculations are the same since the increased number of shares that would be included in the diluted calculation from the assumed exercise of stock equivalents would be anti-dilutive to the net loss in each of the years shown in the financial statements.
	The calculations of net loss per share excluded potentially dilutive securities (consisting of outstanding options, warrants, restricted stock and restricted stock units) of approximately 4.1 million and 1.8 million shares as of March 31, 2015 and 2014, respectively.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In January 2015, the Financial Accounting Standards Board (“FASB”) issued an Accounting Standards Update (“ASU”) which eliminates the concept of extraordinary items. Extraordinary items are events and transactions that are distinguished by their unusual nature and by the infrequency of their occurrence. Eliminating the extraordinary classification simplifies income statement presentation by altogether removing the concept of extraordinary items from consideration. The standard is effective for the fiscal year beginning January 1, 2016. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. The Company does not believe the adoption of this standard will have a material impact on its financial position, results of operations or financial statement disclosures.
	In August 2014, the FASB issued an ASU which requires management to evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern, and to provide certain disclosures when it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued. Since this guidance is primarily around certain disclosures to the financial statements, the Company anticipates no impact on its financial position, results of operations or cash flows from adopting this standard. The Company intends to adopt this guidance at the beginning of its first quarter of fiscal year 2016.
	In May 2014, the FASB issued an ASU which supersedes or replaces nearly all revenue recognition guidance. The new guidance establishes a new control-based revenue recognition model, changes the basis for deciding when revenue is recognized over time or at a point in time and will expand disclosures about revenue. Companies may use either a full retrospective or a modified retrospective approach to adopt this guidance. The Company is evaluating which transition approach to use and its impact, if any, on its financial statements. This ASU is effective for the fiscal year beginning January 1, 2019. Early adoption is not permitted.
Reclassifications	Reclassifications.
	Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Fair Value Measurements	The fair value of the Company’s cash, cash equivalents and available-for-sale investment securities at March 31, 2015 and December 31, 2014 were as follows (in thousands):
		March 31, 2015								December 31, 2014
		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Cash and cash equivalents	$	43,043	$	—	$	—	$	43,043	$	6,346	$	—	$	—	$	6,346
	Short-term investments:
	Commercial paper		—		2,498		—		2,498		—		3,896		—		3,896
	Corporate debt securities		—		42,411		—		42,411		—		59,305		—		59,305
	Total short-term investments		—		44,909		—		44,909		—		63,201		—		63,201
	Long-term investments:
	Corporate debt securities		—		19,612		—		19,612		—		7,087		—		7,087
	Total long-term investments		—		19,612		—		19,612		—		7,087		—		7,087
	Total assets measured at fair value	$	43,043	$	64,521	$	—	$	107,565	$	6,346	$	70,288	$	—	$	76,634
	The Company holds available-for-sale securities that consist of highly liquid, investment grade debt securities. The Company determines the fair value of its available-for-sale securities based upon one or more valuations reported by its investment accounting and reporting service provider. The investment service provider values the securities using a hierarchical security pricing model that relies primarily on valuations provided by an industry-recognized valuation service. Such valuations may be based on trade prices in active markets for identical assets or liabilities (Level 1 inputs) or valuation models using inputs that are observable either directly or indirectly (Level 2 inputs), such as quoted prices for similar assets or liabilities, yield curves, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, and broker and dealer quotes, as well as other relevant economic measures.

Investment_Securities_Tables

Investment Securities (Tables)	3 Months Ended
	Mar. 31, 2015
Investments Schedule [Abstract]
Summary of Investment Securities	The following tables summarize the Company’s investment securities as of March 31, 2015 and December 31, 2014:
		March 31, 2015 (in thousands)
		Cost		Gross		Gross			Fair
				Unrealized		Unrealized			Market
				Gains		Losses			Value
	Available-for-sale securities:
	Commercial paper, short-term	$	2,498	$	—	$	—		$	2,498
	Corporate debt securities, short-term		42,421		5		(15	)		42,411
	Corporate debt securities, long-term		19,627		8		(23	)		19,612
	Total	$	64,546	$	13	$	(38	)	$	64,521
		December 31, 2014 (in thousands)
		Cost		Gross		Gross			Fair
				Unrealized		Unrealized			Market
				Gains		Losses			Value
	Available-for-sale securities:
	Commercial paper, short-term	$	3,896	$	—	$	—		$	3,896
	Corporate debt securities, short-term		59,343		—		(38	)		59,305
	Corporate debt securities, long-term		7,102		—		(15	)		7,087
	Total	$	70,341	$	—	$	(53	)	$	70,288

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Cash, Cash Equivalents and Available-for-Sale Investment Securities	The fair value of the Company’s cash, cash equivalents and available-for-sale investment securities at March 31, 2015 and December 31, 2014 were as follows (in thousands):
		March 31, 2015								December 31, 2014
		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Cash and cash equivalents	$	43,043	$	—	$	—	$	43,043	$	6,346	$	—	$	—	$	6,346
	Short-term investments:
	Commercial paper		—		2,498		—		2,498		—		3,896		—		3,896
	Corporate debt securities		—		42,411		—		42,411		—		59,305		—		59,305
	Total short-term investments		—		44,909		—		44,909		—		63,201		—		63,201
	Long-term investments:
	Corporate debt securities		—		19,612		—		19,612		—		7,087		—		7,087
	Total long-term investments		—		19,612		—		19,612		—		7,087		—		7,087
	Total assets measured at fair value	$	43,043	$	64,521	$	—	$	107,565	$	6,346	$	70,288	$	—	$	76,634

Fixed_Assets_Tables

Fixed Assets (Tables)	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Components of Fixed Assets	Fixed assets consisted of the following at March 31, 2015 and December 31, 2014:
		March 31,			December 31,
		2015			2014
	Manufacturing and lab equipment	$	4,414,172		$	3,837,967
	Office furniture		288,030			278,895
	Computer equipment and software		523,522			471,415
	Leasehold improvements		2,331,748			2,326,963
			7,557,472			6,915,240
	Less accumulated depreciation and amortization		(1,006,411	)		(634,331	)
		$	6,551,061		$	6,280,909
Property Held Under Capital Leases	Property held under capital leases was as follows:
		March 31,			December 31,
		2015			2014
	Manufacturing and lab equipment	$	635,730		$	635,730
	Less accumulated depreciation and amortization		(65,218	)		(16,716	)
		$	570,512		$	619,014

Notes_Payable_Tables

Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Future Minimum Principal Payments on Notes Payable	Future minimum principal payments under the Company’s notes payable are as follows:
	Year ending December 31,
	2015 (9 months)	$	1,400,000
	2016		8,400,000
	2017		8,400,000
	2018		2,800,000
	Total	$	21,000,000

Equity_Awards_Tables

Equity Awards (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock-Based Compensation Expense for Equity Awards to Employees and Non-Employees	The following table summarizes stock-based compensation expense for all equity awards to employees and non-employees:
		Three months ended			Three months ended
		March 31, 2015			March 31, 2014
	Included in research and development	$	468,614		$	174,637
	Included in general and administrative		563,602			261,642
	Total stock-based compensation expense	$	1,032,216		$	436,279
Assumptions Used to Estimate Fair Value of Options Granted	During the first quarter of 2015, the fair value of options granted was estimated using the following weighted-average assumptions:
		Fiscal 2015
	Volatility		69.67	%
	Risk free interest rate		1.56	%
	Dividend yield		0	%
	Weighted-average expected life of option		6.2 years
Summary of Stock Option Activity and Related Information	A summary of the Company’s stock option activity and related information is as follows:
		Options			Weighted-		Weighted-		Aggregate
		Outstanding			Average		Average		Intrinsic
					Exercise		Remaining		Value
					Price		Term
	Balance at December 31, 2014		2,991,656		$	6.67		9.21	$	2,482,181
	Granted		998,991			7.47
	Exercised		(6,666	)		0.18
	Forfeited		(21,068	)		7.78
	Balance at March 31, 2015		3,962,913		$	6.87		9.19	$	12,191,424
	Exercisable at March 31, 2015		593,134		$	5.16		8.54	$	2,842,885

Organization_and_Basis_of_Pres2

Organization and Basis of Presentation - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
	Segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net cash used in operating activities	$9,499,308	$2,829,682
Accumulated deficit	79,069,190		55,562,586
Cash, cash equivalents and investment securities total	$107,600,000
Number of operating segment	1

Summary_of_Significant_Account1

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended		43 Months Ended
Share data in Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015
Accounting Policies [Abstract]
Other-than-temporary impairment charges			$0
Antidilutive securities excluded from computation of earnings per share	4.1	1.8

Asset_Acquisition_Additional_I

Asset Acquisition - Additional Information (Detail) (USD $)	3 Months Ended	0 Months Ended	1 Months Ended
	Mar. 31, 2015	Mar. 17, 2015	Mar. 31, 2015	Mar. 31, 2014
Noncash or Part Noncash Acquisitions [Line Items]
Payments to acquire in-process research and development	$11,880,000
Drug Development Supplies [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Payments to acquire drug development supplies	$900,000
Cephalon Inc [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Additional shares issued in subscription agreement			4,158,750
Share price	$10		$10
Liquidated damages in percent of aggregate purchase price		1.00%
Aggregate cap in percent for liquidated damages		10.00%
Common Stock [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Additional shares issued in subscription agreement				6,031,750
Share price				$9.15
Common Stock [Member] | Cephalon Inc [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Additional shares issued in subscription agreement		1,500,000
Share price		10
Unregistered Common Stock [Member] | Cephalon Inc [Member]
Noncash or Part Noncash Acquisitions [Line Items]
Stock issued for purchase of asset		1,500,000

Investment_Securities_Summary_

Investment Securities - Summary of Investment Securities (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Cost	$64,546	$70,341
Available-for-sale securities, Gross Unrealized Gains	13
Available-for-sale securities, Gross Unrealized Losses	-38	-53
Available-for-sale securities, Fair Market Value	64,521	70,288
Commercial Paper [Member] | Short Term Debt [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Cost	2,498	3,896
Available-for-sale securities, Fair Market Value	2,498	3,896
Corporate Debt Securities [Member] | Short Term Debt [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Cost	42,421	59,343
Available-for-sale securities, Gross Unrealized Gains	5
Available-for-sale securities, Gross Unrealized Losses	-15	-38
Available-for-sale securities, Fair Market Value	42,411	59,305
Corporate Debt Securities [Member] | Long Term Debt [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Cost	19,627	7,102
Available-for-sale securities, Gross Unrealized Gains	8
Available-for-sale securities, Gross Unrealized Losses	-23	-15
Available-for-sale securities, Fair Market Value	$19,612	$7,087

Investment_Securities_Addition

Investment Securities - Additional Information (Detail) (Maximum [Member])	3 Months Ended
	Mar. 31, 2015
Maximum [Member]
Schedule of Available-for-sale Securities [Line Items]
Maturity date for available-for-sale investment securities	18 months

Fair_Value_Measurements_Schedu

Fair Value Measurements - Schedule of Fair Value of Cash, Cash Equivalents and Available-for-Sale Investment Securities (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value	$107,565	$76,634
Cash and Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	43,043	6,346
Short-Term Investments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	44,909	63,201
Short-Term Investments [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	2,498	3,896
Short-Term Investments [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	42,411	59,305
Long-Term Investments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	19,612	7,087
Long-Term Investments [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	19,612	7,087
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value	43,043	6,346
Level 1 [Member] | Cash and Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	43,043	6,346
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets measured at fair value	64,521	70,288
Level 2 [Member] | Short-Term Investments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	44,909	63,201
Level 2 [Member] | Short-Term Investments [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	2,498	3,896
Level 2 [Member] | Short-Term Investments [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	42,411	59,305
Level 2 [Member] | Long-Term Investments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	19,612	7,087
Level 2 [Member] | Long-Term Investments [Member] | Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments	$19,612	$7,087

Fixed_Assets_Components_of_Fix

Fixed Assets - Components of Fixed Assets (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Manufacturing and lab equipment	$4,414,172	$3,837,967
Office furniture	288,030	278,895
Computer equipment and software	523,522	471,415
Leasehold improvements	2,331,748	2,326,963
Fixed Assets - Gross	7,557,472	6,915,240
Less accumulated depreciation and amortization	-1,006,411	-634,331
Fixed Assets - Net	$6,551,061	$6,280,909

Fixed_Assets_Additional_Inform

Fixed Assets - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Property, Plant and Equipment [Abstract]
Depreciation	$372,080	$48,600
Depreciation expense	48,502	0
Capital lease, future remaining minimum payments	$507,000

Fixed_Assets_Property_Held_Und

Fixed Assets - Property Held Under Current Capital Leases (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Capital Leased Assets [Line Items]
Less accumulated depreciation and amortization	($65,218)	($16,716)
Property held under capital leases	570,512	619,014
Manufacturing and Lab Equipment [Member]
Capital Leased Assets [Line Items]
Manufacturing and lab equipment	$635,730	$635,730

Notes_Payable_Additional_Infor

Notes Payable - Additional Information (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2013
Debt Instrument [Line Items]
Loan, maximum borrowing amount		$21,000,000
Loan, additional borrowing option		10,000,000
Final loan fee recorded as debt discount	630,000
Percentage of principal amount of new loan to be paid as final payment		3.00%
Principal and interest payment period commencing after period of interest only payments		30 months
Interest only payments period	12 months
Fixed interest on the advanced amount		8.56%
New loan agreement maturity date		1-Apr-18
Proceeds form offering of equity securities	50,000,000
New Loan Agreement [Member]
Debt Instrument [Line Items]
Contingency payments default interest rate	11.56%
New Loan Agreement [Member] | Common Stock [Member]
Debt Instrument [Line Items]
Warrant to purchase stock, shares	37,849
Useful life	7 years
Warrant to purchase stock,shares	$135,500

Notes_Payable_Future_Minimum_P

Notes Payable - Future Minimum Principal Payments on Notes Payable (Detail) (USD $)	Mar. 31, 2015
Debt Disclosure [Abstract]
2015 (9 months)	$1,400,000
2016	8,400,000
2017	8,400,000
2018	2,800,000
Total	$21,000,000

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	3 Months Ended		0 Months Ended		1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Aug. 04, 2014	Nov. 06, 2013	Dec. 31, 2014
Loss Contingencies [Line Items]
License agreement term	5 years
Additional clinical expenses	$2,700,000	$10,000,000
Estimated cost period	Over a two-year period
CRT [Member]
Loss Contingencies [Line Items]
License expiration term	10 years
Lab Equipment [Member] | Office Space [Member]
Loss Contingencies [Line Items]
Operating leases, expiration dates	Operating leases expiring on various dates through October 2019
Operating leases, rent expense	133,137	69,602
Future minimum lease payments	3,500,000
RXDX-105 and RXDX-106 [Member] | Daiichi Sankyo [Member]
Loss Contingencies [Line Items]
License agreement termination notice period	90 days
RXDX-108 [Member] | Daiichi Sankyo [Member]
Loss Contingencies [Line Items]
License expiration term	10 years
Licensing Agreements [Member]
Loss Contingencies [Line Items]
Annual license payments			3,500,000	7,000,000	10,000,000
Contingent Milestone payments			68,000,000
Licensing Agreements [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Contingent Milestone payments				105,000,000
Royalties percentage				15.00%
Licensing Agreements [Member] | Maximum [Member] | CRT [Member]
Loss Contingencies [Line Items]
Contingent Milestone payments	57,000,000
Licensing Agreements [Member] | Maximum [Member] | RXDX-105 [Member] | Daiichi Sankyo [Member]
Loss Contingencies [Line Items]
Contingent Milestone payments	44,500,000
Licensing Agreements [Member] | Maximum [Member] | RXDX-106 [Member] | Daiichi Sankyo [Member] | Upon Achievement of Development Regulatory and Sales Milestones [Member]
Loss Contingencies [Line Items]
Contingent Milestone payments	47,500,000
Licensing Agreements [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Amount of service to be performed by NMS under the agreement				$1,000,000
Royalties percentage				10.00%

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	3 Months Ended	1 Months Ended				0 Months Ended
	Mar. 31, 2015	Feb. 28, 2014	Mar. 31, 2014	Apr. 30, 2015	Mar. 31, 2015	Mar. 17, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Common stock, shares authorized	150,000,000				150,000,000		150,000,000
Preferred stock, shares authorized	10,000,000				10,000,000		10,000,000
Common Stock, voting right description	Common stock is entitled to one vote, and all shares rank equally as to voting and other matters.
Net proceeds from sale of stock	$50,000,000
Restricted Stock [Member]
Class of Stock [Line Items]
Shares of common stock repurchased	0	400,000
Stock outstanding	37,506				37,506
Future vesting period (year)	2016
Common Stock [Member]
Class of Stock [Line Items]
Stock issued and sold			6,031,750
Sales of common stock, price per share			$9.15
Transaction costs			3,600,000
Gross proceeds from sale of stock			55,200,000
Warrants expiration description	Expire at various dates through September 30, 2021.
Common Stock [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Warrant to purchase stock, shares				16,666
Common stock issued upon conversion by net-exercise basis				11,838
Common Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Warrant to purchase stock, shares	79,516				79,516
Warrant to purchase stock, exercise price per share	$7.52				$7.52
Common Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Warrant to purchase stock, exercise price per share	$3				$3
Cephalon Inc [Member]
Class of Stock [Line Items]
Stock issued and sold					4,158,750
Sales of common stock, price per share	$10				$10
Net proceeds from sale of stock					41,400,000
Transaction costs					$149,000
Cephalon Inc [Member] | Common Stock [Member]
Class of Stock [Line Items]
Stock issued and sold						1,500,000
Sales of common stock, price per share						$10

Equity_Awards_Additional_Infor

Equity Awards - Additional Information (Detail) (USD $)	3 Months Ended	0 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 31, 2015	Jun. 11, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to unvested stock-based awards	$12.50
Options granted during period, maximum contractual term	6 years 2 months 12 days
Estimated weighted-average fair value of stock options granted	$4.68
2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of Restricted Stock	90,000
2014 Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of restricted stock	5 years
2014 Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of restricted stock	4 years
Employee and Non-employee Stock Options [Member] | 2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of equity awards		3,000,000
Number of shares issued for each share subject to a stock option outstanding		1
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to unvested stock-based awards, weighted average period of recognition	3 years 3 months 22 days
Stock Options [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options expiration period from their date of grant	10 years
Stock Options [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total combined voting power	10.00%
Exercise price of option as a percentage of fair market value of common Stock on the grant date	100.00%
Stock Options [Member] | 2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares that remained available for grant	1,250,396
Stock Options [Member] | Stock Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted, term	5 years
Stock Options [Member] | Stock Option One [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of option as a percentage of fair market value of common Stock on the grant date	110.00%
Stock Options [Member] | Inducement Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional equity grants	0
Non-Employee Stock Options [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted during period, maximum contractual term	10 years

Equity_Awards_Summary_of_Stock

Equity Awards - Summary of Stock-Based Compensation Expense for Equity Awards to Employees and Non-Employees (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense for employees and non-employees	$1,032,216	$436,279
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense for employees and non-employees	468,614	174,637
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense for employees and non-employees	$563,602	$261,642

Equity_Awards_Assumptions_Used

Equity Awards - Assumptions Used to Estimate Fair Value of Options Granted (Detail)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Volatility	69.67%
Risk free interest rate	1.56%
Dividend yield	0.00%
Weighted-average expected life of option	6 years 2 months 12 days

Equity_Awards_Summary_of_Stock1

Equity Awards - Summary of Stock Option Activity and Related Information (Detail) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Options Outstanding
Balance at beginning of period	2,991,656
Granted	998,991
Exercised	-6,666
Forfeited	-21,068
Balance at end of period	3,962,913	2,991,656
Exercisable at end of period	593,134
Weighted-Average Exercise Price
Balance at beginning of period	$6.67
Granted	$7.47
Exercised	$0.18
Forfeited	$7.78
Balance at end of period	$6.87	$6.67
Exercisable at end of period	$5.16
Weighted- Average Remaining Contractual Term
Balance at end of period	9 years 2 months 9 days	9 years 2 months 16 days
Exercisable at end of period	8 years 6 months 15 days
Aggregate Intrinsic Value
Balance at end of period	$12,191,424	$2,482,181
Exercisable at end of period	$2,842,885